Skip to main content

Herena Eixarch Ahufinger

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Herena Eixarch Ahufinger

Institutions of which they are part

Postdoctoral researcher
Clinical Neuroimmunology
Vall Hebron Institut de Recerca

Projects

Valorización de una terapia antígeno-específica para el tratamiento disruptivo de la diabetes tipo 1; esclerosis múltiple, miastenia gravis, enfermedad celíaca y artritis reumatoide.

IP: Carmen Espejo Ruiz
Collaborators: Sara Marsal Barril, Herena Eixarch Ahufinger, Helena Borrell Paños, Maria America Lopez Lasanta
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 217313.9
Reference: CPP2021-008475
Duration: 10/02/2022 - 31/12/2025

Ministerio de Ciencia

Rejuvenation of the immune system as a therapeutic approach for progressive multiple sclerosis.

IP: Carmen Espejo Ruiz
Collaborators: Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Breogan Rodriguez Acevedo, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 159720
Reference: PI21/01682
Duration: 01/01/2022 - 30/06/2026

Inmunosenescencia en la esclerosis múltiple. La inmunidad innata como posible diana terapéutica en la esclerosis múltiple.

IP: Carmen Espejo Ruiz
Collaborators: Herena Eixarch Ahufinger, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 135520
Reference: PI18/01146
Duration: 01/01/2019 - 30/06/2023

Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple

IP: Manuel Comabella Lopez
Collaborators: Jaume Sastre Garriga, Jordi Rio Izquierdo, Ingrid Galán Cartaña, Rosalia Horno Ocaña, Herena Eixarch Ahufinger, Incorporació Dr. Manuel Comabella a la RETICS en Esclerosis Múltiple, Carmen Espejo Ruiz, Angela Vidal Jordana, Mireia Castillo Juarez
Funding agency: Instituto de Salud Carlos III
Funding: 225500
Reference: RD16/0015/0004
Duration: 01/01/2017 - 31/12/2022

Related news

Anti-Müllerian hormone had been proposed as a potential biomarker for predicting disease prognosis in women, but this study shows that the observed association is explained by patients’ chronological age.

The Spider-MS tool estimates the probability that a patient will experience various long-term clinical events and will help personalize the follow-up and treatment of each person living with the disease.

The results show that live attenuated vaccines against measles, rubella, mumps and varicella do not increase the risk of relapses in people with multiple sclerosis.

Related professionals

Vicente Serra García

Vicente Serra García

Predoctoral researcher
Cardiovascular Diseases
Read more
Mª del Carmen Gomez Martin

Mª del Carmen Gomez Martin

Research assistant
Multidisciplinary Nursing Research Group
Read more
Silvia Ruiz Álvarez

Silvia Ruiz Álvarez

Administration and Management
Neurovascular Diseases
Read more
Eunice Blanco  Vazquez

Eunice Blanco Vazquez

Administration and Management
Multidisciplinary Nursing Research Group
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.